x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DAB-0012968
| Product Information | |
|---|---|
| Clonality | Monoclonal |
| Isotype | IgG |
| Host Species | Rabbit |
| Reactivity | Human, Mouse, Rat, Hamster, Monkey |
| Applications | WB, IF |
| Product Description | Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Asp39 of human β-galactosidase protein. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | GLB1 |
| UniProt No. | P16278 |
| Gene ID | 2720 |
| Gene Description | β-galactosidase is an essential hydrolase enzyme that catalyzes the hydrolysis of galactose-containing carbohydrates into monosaccharides. Substrates of β-galactosides include lactose, various glycoproteins, ganglioside GM1, and lactosylceramides. β-galactosidase is used widely in molecular biology; for example, isolation of recombinant bacteria during molecular cloning utilizes α-complementation of the bacterial β-galactosidase gene in the presence of a β-gal substrate to identify recombinant clones. In cell biology, Senescence-Associated beta-galactosidase, defined as β-gal activity at pH 6.0, is a widely used marker of replicative senescence. While initially thought to derive from a unique isoform of β-galactosidase expressed specifically in senescent cells, SA-β-gal activity was subsequently shown to result from overexpression and accumulation of β-galactosidase in endogenous lysosomes, and is not specifically required for replicative senescence. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
